|Prof. Arndt Rolfs||Founder, CEO, Chief Medical Officer & Member of Management Board||N/A||N/A||1959|
|Mr. Richard Stoffelen||CFO & Member of Management Board||N/A||N/A||1967|
|Dr. Dirk H. Ehlers||COO, Pres of Clinical Diagnostics & Member of Management Board||N/A||N/A||1961|
|Dr. Volkmar Weckesser Ph.D.||Chief Information Officer & Member of Management Board||N/A||N/A||1967|
|Mr. Robert W. de Deugd||Sr. VP of Sales & Member of Management Board||N/A||N/A||N/A|
Centogene B.V. operates as a commercial-stage rare disease company worldwide. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It operates through two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Diagnostics segment provides genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene B.V. was founded in 2006 and is headquartered in Rostock, Germany.
Centogene N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.